Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Oric Pharmaceuticals (ORIC) Other Gross PP&E Adjustments (2019 - 2026)

Oric Pharmaceuticals filings provide 8 years of Other Gross PP&E Adjustments readings, the most recent being $10.1 million for Q1 2026.

  • Quarterly Other Gross PP&E Adjustments fell 6.75% to $10.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $10.1 million through Mar 2026, down 6.75% year-over-year, with the annual reading at -$8.5 million for FY2025, 110.16% down from the prior year.
  • Other Gross PP&E Adjustments hit $10.1 million in Q1 2026 for Oric Pharmaceuticals, up from -$8.5 million in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at $10.8 million in Q1 2025 and bottomed at -$8.5 million in Q4 2025.
  • Average Other Gross PP&E Adjustments over 5 years is $6.7 million, with a median of $9.5 million recorded in 2024.
  • The largest annual shift saw Other Gross PP&E Adjustments increased 29.55% in 2022 before it tumbled 240.44% in 2024.
  • Oric Pharmaceuticals' Other Gross PP&E Adjustments stood at $2.8 million in 2022, then plummeted by 142.26% to -$1.2 million in 2023, then tumbled by 240.44% to -$4.0 million in 2024, then tumbled by 110.16% to -$8.5 million in 2025, then soared by 219.05% to $10.1 million in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Other Gross PP&E Adjustments are $10.1 million (Q1 2026), -$8.5 million (Q4 2025), and $10.7 million (Q3 2025).